BioCentury
ARTICLE | Clinical News

IV TRC105: Ph III started

February 24, 2017 2:19 AM UTC

Tracon began the international Phase III TAPPAS trial to evaluate weekly IV TRC105 plus once-daily oral Votrient pazopanib vs. Votrient alone in 124 patients. The company has an SPA for the trial from...

BCIQ Company Profiles

Tracon Pharmaceuticals Inc.

BCIQ Target Profiles

Endoglin (CD105) (ENG)